Genedrive (GDR) investor relations material

Commercial and operational progress

• FY26 revenue expected at £1.4 million, up from £1.0 million in FY25, meeting Board expectations.

• Expanded adoption of MT-RNR1 and CYP2C19 tests across NHS, with over 13,000 neonates tested and more than 40 cases of hearing loss prevented.

• CYP2C19 test implementation expanded in UK stroke units and internationally, including Spain, UAE, and Saudi Arabia.

• Collaboration with Thermo Fisher Scientific to develop a high-throughput CYP2C19 kit for centralised labs.

• International revenue expected to contribute about 25% of total income, with two-thirds from MT-RNR1 and one-third from CYP2C19.

Regulatory and strategic initiatives

• NICE final guidance on MT-RNR1 expected around July 2027, with NHS England preparing for national implementation.

• FDA 510(k) submission for CYP2C19 test delayed, with ongoing external studies to support the application.

• Continued engagement with NHS and international health authorities to support adoption and procurement.

Financial and corporate updates

• Equity raise in March 2026 generated net proceeds of £4.9 million; cash position at 30 June 2026 was approximately £3.0 million.

• Monthly cost base is about £0.5 million, supported by R&D tax credit refund.

• Recruitment underway for a new independent Non-Executive Chairman and two Non-Executive Directors.